Strength training linked to lower heart disease risk in women
Peer-Reviewed Publication
Updates every hour. Last Updated: 22-Jun-2026 12:16 ET (22-Jun-2026 16:16 GMT/UTC)
Women who lift weights may have a lower risk of major heart disease, especially when combined with aerobic exercise, according to a new study published today in JACC, the flagship journal of the American College of Cardiology. Findings show that heart health is better understood by looking at overall movement habits, rather than focusing on single behaviors alone, and resistance training can result in additional health benefits when incorporated into an active lifestyle.
A research paper by scientists at Aerospace Information Research Institute, Chinese Academy of Sciences developed a dual-mode wireless microsystem that enables simultaneous recording of spikes, local field potentials (LFPs), and dopamine (DA)-related electrochemical signals on microelectrode arrays.
The research paper, published on May 21, 2026 in the journal Cyborg and Bionic Systems.
New paper argues current exercise and protein guidelines aim too low for healthy ageing.
Cells have surface receptors that couple to proteins and other molecules to initiate or inhibit certain behaviors. Typically, the number of these receptors increases as the cell matures, but researchers have now identified that one receptor influences cell behavior much earlier than previously thought and appears to help trigger the cell differentiation process to form neurons.
River experts say new satellite technology holds the promise of protecting water quality around the world. In a paper published in the journal Nature Water hydrology experts from around the world explained how scientists can use new tools such as satellite remote sensing to study water quality and the health and stressors of all of the world’s rivers.
CAMBRIDGE, Mass. / HONG KONG — June 17, 2026 — Insilico Medicine (“Insilico”, HKEX: 3696), a clinical-stage biotechnology company powered by generative artificial intelligence (AI), today announced it has achieved the first clinical milestone in its co-development collaboration with Hygtia Therapeutics with the completion of first-in-human dosing in the Phase I study of ISM8969. ISM8969 is a potentially best-in-class, orally available, brain-penetrant small-molecule inhibitor of the NLRP3 inflammasome being developed to treat chronic neuroinflammation and central nervous system (CNS) disorders, including Parkinson’s disease.